Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

Are Cloud Robotics Are a Game-Changer?
16:47 - “The Industries of the Future” Author Alec Ross discusses cloud robotics and the future of robot technology on “Bloomberg West.” (Source: Bloomberg)
  • Is There a Tech Talent Shortage in Silicon Valley?
  • Blackberry Cuts Jobs in Push to Profit
  • Bloomberg Businessweek: The Female Solidarity